Personalized

Europe Precision Diagnostics Market Report 2022: The Era of Personalized Medicine is Dawning, Fueling Industry Growth

Europe Precision Diagnostics Market Report 2022: The Era of Personalized Medicine is Dawning, Fueling Industry Growth

Dublin, Nov. 24, 2022 (GLOBE NEWSWIRE) — The report “Europe Precision Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type, Application, and End User” has been added to from ResearchAndMarkets.com offer. Europe Precision Diagnostics Market is expected to grow from US$23,317.64 million in 2022 to US$48,500.85 million by 2028. It …

Europe Precision Diagnostics Market Report 2022: The Era of Personalized Medicine is Dawning, Fueling Industry Growth Read More »

Data Standards Fuel Advances in Personalized Medicine at VA

Data Standards Fuel Advances in Personalized Medicine at VA

VA turns to data standards to improve health care as more veterans use personal health monitoring devices. The Department of Veterans Affairs is leveraging data standards to leverage new information from smart devices and improve personalized medicine for veterans. “Our job is to look at where we need to be in health care, not where …

Data Standards Fuel Advances in Personalized Medicine at VA Read More »

SNU Bundang Hospital and Cipherome, Inc. Enter into Memorandum of Understanding for Personalized Medicine Cooperation

SNU Bundang Hospital and Cipherome, Inc. Enter into Memorandum of Understanding for Personalized Medicine Cooperation

Cooperation for the establishment of the precision medicine research platform at the SNUBH Biomedical Research Institute SAN JOSE, CA, November 16, 2022–(BUSINESS WIRE)–Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it entered into the Memorandum of Understanding on November 15, 2022 to standardize clinical-genomic research at using Cipherome, Inc.’s precision medicine research …

SNU Bundang Hospital and Cipherome, Inc. Enter into Memorandum of Understanding for Personalized Medicine Cooperation Read More »

GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab

GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab

Geneva, Switzerland–(BUSINESS WIRE)–Regulatory news: GeNeuro (Euronext Paris: CH0308403085 – GNRO) (Paris:GNRO), a biopharmaceutical company specializing in stopping the causal factors behind the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and post-acute sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the enrollment of the first patients in …

GeNeuro Announces Enrollment of First Patients at Five Swiss Centers in First Long COVID Personalized Medicine Clinical Trial Evaluating Temelimab Read More »